2 months ago
Oregon Live
An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening — but the anxiously awaited new data leaves unclear how much difference that might make in people’s lives. Lecanemab delayed patients’ worsening by about five months over the course of the 18-month study, Eisai’s Dr. Michael Irizarry told The Associated Press. Also, lecanemab recipients were 31% less likely to advance to the next stage of the disease during the study. The trial is important because it shows a drug that attacks a sticky protein called amyloid -- considered one of several culprits behind Alzheimer’s -- can delay disease progression, said Maria Carrillo, chief science officer for the Alzheimer’s Association. Eisai said Tuesday the deaths can’t be attributed to the Alzheimer’s drug.
Continue reading...
